Deferoxamine-DBCO
Based on 1 Customer Validation
Deferoxamine-DBCO (DFO-DBCO) is a bifunctional small-molecule synthetic building block obtained by covalent conjugation of the DFO metal-chelating group with DBCO, and is a bifunctional chelator. Deferoxamine-DBCO efficiently chelates radioactive metals (such as 89Zr) through the DFO moiety to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA and monoclonal antibodies) through the DBCO moiety under bioorthogonal conditions to accomplish targeted conjugation. Deferoxamine-DBCO is applicable to research related to bioconjugation chemistry and the preparation of PET radiotracer probes.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 96.44%
- CAS 番号: 2359695-48-8
- 分子式: C44H61N7O10
- 分子量:848.00
-
保管条件:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Radionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
RDC Bifunctional Chelator |
体外実験
Deferoxamine-DBCO (DFO-DBCO) reacts with azide-functionalized ultrasmall C' dots silica nanoparticles via SPAAC copper-free click chemistry, introducing 89Zr chelating groups onto the nanoparticle surface[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2359695-48-8
-
性状 Solid
-
分子量 848.00
-
分子式 C44H61N7O10
-
Color White to off-white
-
SMILES
CC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N1CC2=C(C=CC=C2)C#CC3=C1C=CC=C3)=O)=O)O)=O)=O)O)=O)=O)O)=O
-
別名
DFO-DBCO
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (117.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1792 mL | 5.8962 mL | 11.7925 mL | 29.4811 mL |
| 5 mM | 0.2358 mL | 1.1792 mL | 2.3585 mL | 5.8962 mL | |
| 10 mM | 0.1179 mL | 0.5896 mL | 1.1792 mL | 2.9481 mL | |
| 15 mM | 0.0786 mL | 0.3931 mL | 0.7862 mL | 1.9654 mL | |
| 20 mM | 0.0590 mL | 0.2948 mL | 0.5896 mL | 1.4741 mL | |
| 25 mM | 0.0472 mL | 0.2358 mL | 0.4717 mL | 1.1792 mL | |
| 30 mM | 0.0393 mL | 0.1965 mL | 0.3931 mL | 0.9827 mL | |
| 40 mM | 0.0295 mL | 0.1474 mL | 0.2948 mL | 0.7370 mL | |
| 50 mM | 0.0236 mL | 0.1179 mL | 0.2358 mL | 0.5896 mL | |
| 60 mM | 0.0197 mL | 0.0983 mL | 0.1965 mL | 0.4914 mL | |
| 80 mM | 0.0147 mL | 0.0737 mL | 0.1474 mL | 0.3685 mL | |
| 100 mM | 0.0118 mL | 0.0590 mL | 0.1179 mL | 0.2948 mL |
Keywords
- Deferoxamine-DBCO
- 2359695-48-8
- DFO-DBCO
- Biochemical Assay Reagents
- Radionuclide-Drug Conjugates (RDCs)
- Drug Intermediate
- Drug Iintermediate
- endolysosomal compartment
- EGFR signaling inhibitor
- HT1080 WT cells
- non-small cell lung cancer
- MT1-MMP (MMP-14) targeting vector
- HT1080 KO cells
- enhanced permeability and retention effect
- pEGFR
- bone sarcoma
- ECLC26 cells
- Inhibitor
- inhibitor
- inhibit